Citation United States Department of Health and Human Services (DHHS), Public Health Service (PHS), Centers for Disease Control (CDC) / Food and Drug Administration (FDA), Vaccine Adverse Event Reporting System (VAERS) 1990 - 08/05/2022, CDC WONDER On-line Database. Accessed at http://wonder.cdc.gov/vaers.html on Aug 18, 2022 1:33:27 AM

Query Criteria:Event Category:Death State / Territory:California Vaccine Manufacturer:PFIZER\BIONTECH Vaccine Products:COVID19 VACCINE (COVID19) VAERS ID:All Group By:Symptoms; Vaccine Type; Age; VAERS ID; State / Territory

=========

Disclaimer

VAERS accepts reports of adverse events that occur following vaccination. Anyone, including healthcare providers, vaccine manufacturers, and the public, can submit reports to the system. While very important in monitoring vaccine safety, VAERS reports alone cannot be used to determine if a vaccine caused or contributed to an adverse event or illness. Vaccine providers are encouraged to report any clinically significant health problem following vaccination to VAERS even if they are not sure if the vaccine was the cause. In some situations, reporting to VAERS is required of healthcare providers and vaccine manufacturers. VAERS reports may contain information that is incomplete, inaccurate, coincidental, or unverifiable. Reports to VAERS can also be biased. As a result, there are limitations on how the data can be used scientifically. Data from VAERS reports should always be interpreted with these limitations in mind. The strengths of VAERS are that it is national in scope and can often quickly detect an early hint or warning of a safety problem with a vaccine. VAERS is one component of CDC's and FDA's multifaceted approach to monitoring safety after vaccines are licensed or authorized for use. There are multiple, complementary systems that CDC and FDA use to capture and validate data from different sources. VAERS is designed to rapidly detect unusual or unexpected patterns of adverse events, also referred to as "safety signals." If a possible safety signal is found in VAERS, further analysis is performed with other safety systems, such as the CDC’s Vaccine Safety Datalink (VSD) and Clinical Immunization Safety Assessment (CISA) Project, or in the FDA BEST (Biologics Effectiveness and Safety) system. These systems are less impacted by the limitations of spontaneous and voluntary reporting in VAERS and can better assess possible links between vaccination and adverse events. Additionally, CDC and FDA cannot provide individual medical advice regarding any report to VAERS. Key considerations and limitations of VAERS data:

The number of reports alone cannot be interpreted as evidence of a causal association between a vaccine and an adverse event, or as evidence about the existence, severity, frequency, or rates of problems associated with vaccines. Reports may include incomplete, inaccurate, coincidental, and unverified information. VAERS does not obtain follow up records on every report. If a report is classified as serious, VAERS requests additional information, such as health records, to further evaluate the report. VAERS data are limited to vaccine adverse event reports received between 1990 and the most recent date for which data are available. VAERS data do not represent all known safety information for a vaccine and should be interpreted in the context of other scientific information.

VAERS data available to the public include only the initial report data to VAERS. Updated data which contains data from medical records and corrections reported during follow up are used by the government for analysis. However, for numerous reasons including data consistency, these amended data are not available to the public.

Additionally, reports to VAERS that appear to be false or fabricated with the intent to mislead CDC and FDA may be reviewed before they are added to the VAERS database. Knowingly filing a false VAERS report is a violation of Federal law (18 U.S. Code § 1001) punishable by fine and imprisonment.

When a company decides it would like to sell a drug or vaccine in Canada, it files a submission with Health Canada. A new drug submission contains detailed scientific information about the drug's safety, efficacy and quality. Health Canada scientific reviewers evaluate data to assess the potential benefits and risks of a drug or vaccine. They also review the information that will be provided to health care practitioners and consumers about the product. After the review, we may authorize the drug or vaccine for sale in Canada only if the benefits of the product outweigh the potential risks.

COVID-19 Reopening Data from Associated Press and Kantar Media

Access regularly updated data from The Associated Press and Kantar Media containing information on events at the global, national and state levels as economies reopen following the coronavirus pandemic via AP Planner.

AP Planner is a paid service from The Associated Press & Kantar Media.

The four data files below feature the following event types:

• Environmental, Social and Governance (ESG): Events related the factors that measure the sustainability and societal impact of an investment in a company or business.
• Healthcare, Pharmaceuticals and Bio Tech: Health care providers and services, health care equipment and supplies, and health care technology companies. Drug and vaccine production, as well as biological substances for the purposes of drug discovery and diagnostic development.
• Politics: U.S. political news and events.
• Diversity and Discrimination: News and events related to race, religion, gender, sexuality, disability and age.

All data is compiled by a dedicated staff with over 15 years of forward planning research experience, employing data verification and processes designed to provide reliable and up-to-date information.

The data can be used to help:

• Provide signals to investors on how to act and at what speed based on the types of events returning across industries.
• Analyze risk associated with companies based on when they're reopening.
• Retain your own customer base based on reopening dates for vendors and competitors.
• Track COVID regulations to prepare inventory and guest policies.

The following data files are samples - if you are interested in licensing the full, regularly updated database, please contact Opal Barclay (obarclay@ap.org) at The Associated Press or Click on Request Access Button above.

​

***

FAQs

Why does AP and Kantar compile this data?_ The data is sourced from AP Planner, a product offered by The Associated Press and Kantar Media. AP Planner is a searchable database of future events that is updated daily and intended for research, not publication.

What information does AP Planner contain?_ AP Planner is global in scope and contains more than 100,000 U.S. and international events from the world of news, current affairs, politics, business, lifestyle and more - all searchable up to 12 months ahead.

Where does the information come from?_ AP Planner aggregates listings from tens of thousands of organizations worldwide. Our research staff monitors over 350,000 websites and uses a verity of secondary sources including press releases, corporate announcements and other outlets to ensure accuracy.

How can I be confident of the data's quality and accuracy?_ We have a dedicated research staff with over 15 years of forward planning research experience. They employ data verification and updating processes designed to provide our customers with completely reliable and up-to-date information.

Can I export data into other applications?_ Yes, AP Planner data can be exported as an Excel file or an Outlook calendar file. The data is also accessible via API.

Who can I contact to learn more about AP Planner?_ Opal Barclay, obarclay@ap.org.

The file contains 9,921 tweets labelled with the concerns towards vaccines. There are 3 columns in the file: - ID of the tweet in a string format, appended with a "t" (to make it easier to work with on spreadsheet softwares). - The tweet text - The different labels (vaccine concerns) expressed in the tweet, seperated by spaces.

List of the 12 different vaccine concerns in the dataset: - [unnecessary]: The tweet indicates vaccines are unnecessary, or that alternate cures are better. - [mandatory]: Against mandatory vaccination — The tweet suggests that vaccines should not be made mandatory. - [pharma]: Against Big Pharma — The tweet indicates that the Big Pharmaceutical companies are just trying to earn money, or the tweet is against such companies in general because of their history. - [conspiracy]: Deeper Conspiracy — The tweet suggests some deeper conspiracy, and not just that the Big Pharma want to make money (e.g., vaccines are being used to track people, COVID is a hoax) - [political]: Political side of vaccines — The tweet expresses concerns that the governments / politicians are pushing their own agenda though the vaccines. - [country]: Country of origin — The tweet is against some vaccine because of the country where it was developed / manufactured - [rushed]: Untested / Rushed Process — The tweet expresses concerns that the vaccines have not been tested properly or that the published data is not accurate. - [ingredients]: Vaccine Ingredients / technology — The tweet expresses concerns about the ingredients present in the vaccines (eg. fetal cells, chemicals) or the technology used (e.g., mRNA vaccines can change your DNA) - [side-effect]: Side Effects / Deaths — The tweet expresses concerns about the side effects of the vaccines, including deaths caused. - [ineffective]: Vaccine is ineffective — The tweet expresses concerns that the vaccines are not effective enough and are useless. - [religious]: Religious Reasons — The tweet is against vaccines because of religious reasons - [none]: No specific reason stated in the tweet, or some reason other than the given ones.

BackgroundAmidst widespread public health recommendations and availability of COVID-19 vaccinations, half of South African adults are vaccinated against COVID-19. This study investigated the socio-behavioral determinants of vaccine hesitancy in South Africa, where vaccine hesitancy was separated into unwilling ness and uncertainty to take a COVID-19 vaccine.MethodsData was collected from a large-scale public survey during June–October 2021 that included online and telephonic surveys. Vaccination hesitancy was based on the question “When available, would you take the COVID 19 vaccine?,” with responses categorized into those who were willing, unwilling, and uncertain about taking a COVID-19 vaccine. Multinomial regression examined the association between socio-behavioral variables and vaccine hesitancy.ResultsOverall, 73.8% reported they would definitely or probably take the vaccine, 16.4% were uncertain and 9.9% reported they probably or definitely would not (n = 16,988). Younger age, White and Colored population groups, no influenza vaccination history, previous vaccination refusal, knowing someone who experienced a serious vaccination side-effect, misperceptions about vaccine benefits, cultural or religious discouragement from taking a COVID-19 vaccination, lack of governmental confidence, concerns about side-effects, perceived lack of safety information, and lack of trust in the pharmaceutical industry and in the information from health care providers were all associated with higher odds of being uncertain and unwilling to take a COVID-19 vaccination. Strengths of association for unwillingness and uncertainty varied by the explanatory variables. Concern about effectiveness due to fast development was associated with uncertainty to take the vaccine but not with unwillingness. Concerns about side-effects had stronger associations with uncertainty than with unwillingness, while previous vaccine refusal, misperceptions of the protective benefits of vaccines, White population group, religious/cultural discouragement, and lack of trust in the pharmaceutical industry and health care providers’ information had stronger associations with unwillingness than uncertainty.ConclusionThe determinants of COVID-19 vaccine hesitancy should be addressed in interventions to improve vaccine uptake. Public health interventions and health communication can be prioritized and tailored to the different forms of vaccination hesitancy.